Optimization of Protein and Peptide Drugs Based on the Mechanisms of Kidney Clearance
- PMID: 29848260
- DOI: 10.2174/0929866525666180530122835
Optimization of Protein and Peptide Drugs Based on the Mechanisms of Kidney Clearance
Abstract
Background: Development of proteins and peptides into drugs has been considered as a promising strategy to target certain diseases. However, only few proteins and peptides have been approved as new drugs into the market each year. One major problem is that proteins and peptides often exhibit short plasma half-life times, which limits the application for their clinical use. In most cases a short half-life time is not effective to deliver sufficient amount of drugs to the target organs and tissues, which is generally caused by fast renal clearance and low plasma stability due to proteolytic degradation during systemic circulation, because that the most common clearance pathway of small proteins and peptides is through glomerular filtration by the kidneys.
Conclusion: In this review, enzymatic degradation of proteins and peptides were discussed. Furthermore, several approaches to lengthen the half-life of peptides and proteins drugs based on the unique structures of glomerular capillary wall and the mechanisms of glomerular filtration were summarized, such as increasing the size and hydrodynamic diameter; increasing the negative charge to delay the filtration; increasing plasma protein binding to decrease plasma clearance.
Keywords: Kidney clearance; enzymatic degradation; glomerular filtration; peptides drugs; plasma half-life; protein drugs..
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
Similar articles
-
Peptide and Low Molecular Weight Proteins Based Kidney Targeted Drug Delivery Systems.Protein Pept Lett. 2018;25(6):522-527. doi: 10.2174/0929866525666180530123441. Protein Pept Lett. 2018. PMID: 29848259 Review.
-
Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs.Br J Clin Pharmacol. 2012 Jul;74(1):66-74. doi: 10.1111/j.1365-2125.2012.04172.x. Br J Clin Pharmacol. 2012. PMID: 22242561 Free PMC article.
-
Current strategies in extending half-lives of therapeutic proteins.J Control Release. 2019 May 10;301:176-189. doi: 10.1016/j.jconrel.2019.02.016. Epub 2019 Mar 5. J Control Release. 2019. PMID: 30849445 Review.
-
Strategies to improve plasma half life time of peptide and protein drugs.Amino Acids. 2006 Jun;30(4):351-67. doi: 10.1007/s00726-005-0289-3. Epub 2006 Apr 20. Amino Acids. 2006. PMID: 16622600 Review.
-
Ontogeny of hepatic and renal systemic clearance pathways in infants: part II.Clin Pharmacokinet. 2002;41(13):1077-94. doi: 10.2165/00003088-200241130-00005. Clin Pharmacokinet. 2002. PMID: 12403644 Review.
Cited by
-
Peptide Drug Conjugates and Their Role in Cancer Therapy.Int J Mol Sci. 2023 Jan 3;24(1):829. doi: 10.3390/ijms24010829. Int J Mol Sci. 2023. PMID: 36614268 Free PMC article. Review.
-
Rational Vaccinology: Harnessing Nanoscale Chemical Design for Cancer Immunotherapy.ACS Cent Sci. 2022 Jun 22;8(6):692-704. doi: 10.1021/acscentsci.2c00227. Epub 2022 May 20. ACS Cent Sci. 2022. PMID: 35756370 Free PMC article. Review.
-
Advance in vasculogenic mimicry in ovarian cancer (Review).Oncol Lett. 2023 Sep 5;26(4):456. doi: 10.3892/ol.2023.14043. eCollection 2023 Oct. Oncol Lett. 2023. PMID: 37736556 Free PMC article. Review.
-
Population Pharmacokinetic Modeling of Certepetide in Human Subjects With Metastatic Pancreatic Ductal Adenocarcinoma.Clin Pharmacol Drug Dev. 2025 Mar;14(3):240-251. doi: 10.1002/cpdd.1502. Epub 2025 Jan 9. Clin Pharmacol Drug Dev. 2025. PMID: 39789733 Free PMC article.
-
Site-Specific Antibody Conjugation Strategy to Functionalize Virus-Based Nanoparticles.Bioconjug Chem. 2020 May 20;31(5):1408-1416. doi: 10.1021/acs.bioconjchem.0c00118. Epub 2020 Apr 13. Bioconjug Chem. 2020. PMID: 32281790 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical